Navigation Links
Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Date:11/1/2011

HAYWARD, Calif., Nov. 1, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced that it will be presenting data on arhalofenate, a potential best-in-class treatment for gout, at the 2011 ACR/AHP Annual Scientific Meeting on Wednesday, November 9, 2011 in Chicago, IL.  The presentation will describe the results of a pooled analysis of four Phase 2 studies in patients with type 2 diabetes, a subset of which exhibited hyperuricemia. The analysis shows that the patients experienced statistically and clinically significant reductions in serum uric acid that were fully retained in patients with mild-to-moderate renal insufficiency.  

Presentation Title: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes"

Session Title: Metabolic and Crystal Arthropathies II: Concurrent Session on the Anti-Gout Medications – Dosing, Adverse Effects, and Economic Burden

Date/Time:  Wednesday, November 9, 2011 from 10:15 AM - 10:30 AM CST

Location: McCormick Place Convention Center: W 474 A

About Hyperuricemia and Gout

Gout is a chronic, progressive rheumatic disease, caused by an inflammatory response to uric acid crystals deposited in joints and soft tissues as a result of excess uric acid in the blood (hyperuricemia). Elevated sUA levels cause urate crystals for form in joints triggering acute arthritic flares, chronic destructive arthropathy and formation of tophi.  According to the NHANES (2007-2008) study, the incidence of hyperuricemia in the US is over 45 million and over 8 million have progressed to a gout diagnosis.  

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases. The company has three clinical-stage compounds: arhalofenate, which has completed four Phase 2 trials and is currently conducting three Phase 2b trials for gout; MBX-2982, which has recently completed a Phase 2a trial in patients with Type 2 diabetes; and MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia.  

For additional information about Metabolex and its development pipeline, visit www.metabolex.com.

Contact:
Donald Hill
Metabolex, Inc.
(510) 293-8800
dhill@metabolex.com


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
2. Metabolex Initiates Phase 1 Trial of MBX-2982
3. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Boehringer Ingelheim announced today that it has been recognized ... the ninth time that the company received a perfect ... to Work for LGBT Equality. Administered by the Human ... report on corporate policies and practices related to workplace ... "We are committed to creating an ...
(Date:12/8/2016)... December 8, 2016 According ... Market by Product (Actual Sugars, Sugar Alcohols, Artificial ... Diluent, Tonicity Agents), Formulation (Oral, Topical, Parenteral) - ... market has witnessed healthy growth during the last ... CAGR of 4.3% between 2016 and 2021 to ...
(Date:12/8/2016)... According to a new market research report "Wearable Medical Devices ... End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), Distribution Channel (Pharmacy, ... terms of value, is projected to reach 12.14 Billion by 2021 from ... forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... surgery as possible. With this in mind, SIGVARIS has created a new line ... clot) during bed rest and provide the benefits of graduated compression when transitioning ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... planning services from offices headquartered in Hamilton County, is embarking on a charity ... LuvFurMutts specializes in finding new homes for orphaned or neglected senior dogs in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/8/2016)... Bay St. Louis, MS (PRWEB) , ... December 08, 2016 , ... ... with offices that serve commercial and residential clients in and around the Hancock County ... community support for the Hancock County Food Pantry. , The Hancock County Food Pantry ...
Breaking Medicine News(10 mins):